<DOC>
	<DOCNO>NCT02679196</DOCNO>
	<brief_summary>Multiple ascend dose study evaluate safety/tolerability , pharmacokinetic pharmacodynamics effect KA2237 ( PI3 Kinase p110β/δ Inhibitor ) patient B Cell Lymphoma determine maximum tolerate dose ( MTD ) Part I study . In Part II , patient B cell lymphoma treat KA2237 MTD evaluate safety efficacy patient population .</brief_summary>
	<brief_title>The Safety , Pharmacokinetic Pharmacodynamic Effect KA2237 ( PI3 Kinase p110β/δ Inhibitor ) In B Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>1 . Age ≥18 year screen visit . 2 . Has give write consent participate study . 3 . Has Bcell lymphoma refractory intolerant establish therapy know provide clinical benefit condition receive rituximab single agent combination therapy . 4 . Disease status requirement : Measurable disease define presence ≥ 1 nodal lesion measure ≥ 1.5 cm single dimension assess Xray Computed Tomography ( CT ) ( Positron Emission Tomography ( PET/CT ) , magnetic resonance image [ MRI ] 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 6 . For men woman childbearing potential , willing use adequate contraception 1 . Subject chronic alcoholic ( intake &gt; 35 unit alcohol ( &gt; 5 bottle wine weekly ) ) drug abuser 2 . Subject medical psychiatric condition , opinion Investigator , may compromise subject 's ability participate study 3 . Female subject breastfeed , pregnant , plan become pregnant study within 3 month follow last dose investigational product 4 . Subjects current recent history , determine Investigator , severe , progressive , and/or uncontrolled renal disease ( estimate glomerular filtration rate ( eGFR ) &lt; 30ml/min ) , hepatic ( Alanine transaminase ( ALT ) 2.5 time upper limit normal ( &gt; 2.5xULN ) , bilirubin &gt; 2x ULN ) , hematological ( absolute neutrophil count ( ANC ) &lt; 1.0 x 109/L , platelet count &lt; 75x109/L require regular platelet transfusion maintain platelet count ≥ 75 x 109/L , hemoglobin &lt; 9g/dL ) , endocrine ( glycated Haemoglobin ( HbA1c ) &gt; 7 % random glucose &gt; 200mg/dL ) , pulmonary ( Forced Expiratory Volume 1 second ( FEV1 ) &lt; 70 % predict value ) , cardiac ( New York Heart Association ( NYHA ) ) class III/IV , neurological disease 5 . Has allogeneic stem cell transplant current active graftversushostdisease . 6 . Has know active central nervous system involvement malignancy . 7 . Has active , serious infection require systemic therapy . Patients may receive prophylactic antibiotic antiviral therapy discretion treat physician . 8 . Has positive test human immunodeficiency virus ( HIV ) antibody . 9 . Has active hepatitis B C. Patients serologic evidence prior exposure eligible . 10 . Diseaserelated exclusion Had treatment short course corticosteroid ( &gt; 10mg daily prednisone equivalent ) symptom relief within 1week prior screening . Has poorly control diabetes mellitus ( HbA1c &gt; 7 % random glucose &gt; 200mg/dL ) Known tuberculosis ( TB ) disease latent TB infection Has chronic , active colitis 11 . Medication related exclusion Had alemtuzumab therapy within 12weeks prior screening . Has take medication potent inhibitor inducer cytochrome P450 3A4 ( CYP3A4 ) within 1week prior screening . The subject previously participate study . The subject participate currently participate another study investigational medicine medical device ( radiotherapy , radioimmunotherapy , biological therapy , chemotherapy ) , within 4weeks prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>